TY - JOUR
T1 - Allogeneic tumor enhancement by levamisole, a new immunostimulatory compound
T2 - Studies on cell-mediated immunity and humoral antibody response
AU - Mantovani, A.
AU - Spreafico, F.
PY - 1975
Y1 - 1975
N2 - C3H mice transplanted with the incompatible L1210 leukemia exhibited progressive tumor takes in a high percentage of cases when treated with the same course of the chemical immunostimulant levamisole which could induce a marked rise in the immune response towards allogeneic erythrocytes. Investigations of the specific antitumoral immune reactivity revealed in progressor mice a depression of cell-mediated immunity and serum cytotoxic antibodies and an increased serum blocking activity. The relevance of these immunological modifications to enhanced tumor growth and the possible mechanisms of action of the immunostimulant are discussed in this paper.
AB - C3H mice transplanted with the incompatible L1210 leukemia exhibited progressive tumor takes in a high percentage of cases when treated with the same course of the chemical immunostimulant levamisole which could induce a marked rise in the immune response towards allogeneic erythrocytes. Investigations of the specific antitumoral immune reactivity revealed in progressor mice a depression of cell-mediated immunity and serum cytotoxic antibodies and an increased serum blocking activity. The relevance of these immunological modifications to enhanced tumor growth and the possible mechanisms of action of the immunostimulant are discussed in this paper.
UR - http://www.scopus.com/inward/record.url?scp=0016713622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016713622&partnerID=8YFLogxK
U2 - 10.1016/0014-2964(75)90125-5
DO - 10.1016/0014-2964(75)90125-5
M3 - Article
C2 - 1222761
AN - SCOPUS:0016713622
SN - 0014-2964
VL - 11
SP - 537
EP - 544
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 8
ER -